FDA triple header. Food and Drug Administration.
Smart
T
T
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002648:Child; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage / Q000627:therapeutic use; D019259:Lamivudine; D009154:Mutation; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use; D016879:Salvage Therapy; D019258:Saquinavir; D018119:Stavudine / Q000008:administration & dosage / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011804:Quinolines; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine; D018119:Stavudine; D016049:Didanosine; D019258:Saquinavir